Volume 12, Issue 4 (12-2025)
NBR 2025, 12(4): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
hedayati M, zahmatkesh M, amin K, gholinia H. Comparison of uric acid serum level and other risk factors in patients with hypertrophic cardiomyopathy with healthy people. NBR 2025; 12 (4)
URL: http://nbr.khu.ac.ir/article-1-3751-en.html
URL: http://nbr.khu.ac.ir/article-1-3751-en.html
, drmohammad.hedayati@yahoo.com
Abstract: (1428 Views)
Introduction:Hypertrophic cardiomyopathy(HCM)is a common inherited disease that can lead to acute cardiac complications.Since uric acid level is recognized as a long-term predictor for some cardiac diseases,this study aimed to compare serum uric acid levels and other risk factors between patients with HCM and healthy individuals.
Methods:This cross-sectional study was conducted on100individuals referred to a cardiology clinic.Participants were divided into two groups of50:those diagnosed with hypertrophic cardiomyopathy and non-affected individuals,who were followed for one year.Patients were compared based on age, history of alcohol consumption,myocardial infarction,and measured uric acid levels.
Results:The study found that variables such as age(P<0.001), body mass index(BMI)(P=0.017), history of alcohol consumption(P=0.006),repeat percutaneous coronary intervention (PCI)(P=0.022),myocardial infarction(P=0.041),and cardiac-related death(P=0.003)were significantly associated with HCM patients compared to the control group. Overall, major adverse cardiac events(MACE)were also significantly linked to the case group(P<0.001).However,no significant association was found between uric acid levels and any of the variables.In the long-term analysis,smoking was the only factor that increased the risk of cardiovascular events by nearly27-fold.
Conclusion:The results indicated that age, history of alcohol consumption, and prior myocardial infarction are risk factors associated with HCM.Uric acid levels did not prove to be a predictor of cardiovascular events within one year in patients with hypertrophic cardiomyopathy.
Methods:This cross-sectional study was conducted on100individuals referred to a cardiology clinic.Participants were divided into two groups of50:those diagnosed with hypertrophic cardiomyopathy and non-affected individuals,who were followed for one year.Patients were compared based on age, history of alcohol consumption,myocardial infarction,and measured uric acid levels.
Results:The study found that variables such as age(P<0.001), body mass index(BMI)(P=0.017), history of alcohol consumption(P=0.006),repeat percutaneous coronary intervention (PCI)(P=0.022),myocardial infarction(P=0.041),and cardiac-related death(P=0.003)were significantly associated with HCM patients compared to the control group. Overall, major adverse cardiac events(MACE)were also significantly linked to the case group(P<0.001).However,no significant association was found between uric acid levels and any of the variables.In the long-term analysis,smoking was the only factor that increased the risk of cardiovascular events by nearly27-fold.
Conclusion:The results indicated that age, history of alcohol consumption, and prior myocardial infarction are risk factors associated with HCM.Uric acid levels did not prove to be a predictor of cardiovascular events within one year in patients with hypertrophic cardiomyopathy.
Type of Study: Original Article |
Subject:
Cell and Molecular Biology
Received: 2025/11/7 | Revised: 2025/12/27 | Accepted: 2025/12/16 | Published: 2026/04/11 | ePublished: 2026/04/11
Received: 2025/11/7 | Revised: 2025/12/27 | Accepted: 2025/12/16 | Published: 2026/04/11 | ePublished: 2026/04/11
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© 2026 CC BY-NC 4.0 | Nova Biologica Reperta
Designed & Developed by : Yektaweb